BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
An engineered oncolytic herpes virus expressing a full-length α-CD47 mAb for the treatment of GBM
An engineered oncolytic herpes virus expressing a full-length α-CD47 mAb for the treatment of GBM is a funding opportunity from BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, up to 176146, closing August 31, 2027.
Aug 31, 2027
(396d left)Overview
PROJECT SUMMARY – PROJECT 1 The combination of oncolytic virotherapy (OV) and monoclonal antibody (mAb) immunotherapy has great potential for the treatment of glioblastoma (GBM), the most common malignant brain tumor without a cure. An OV carrying a mAb-coding gene can produce and release the mAb drug specifically…